Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening.

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Drug Development

Background:

• Cardiotoxicity is a major cause of drug failure in clinical trials.
• Need for reliable in vitro models for preclinical drug toxicity screening and personalized therapy.

Purpose of the Study:

• To fabricate and characterize a human cardiac tissue model for high-throughput drug toxicity studies.
• To evaluate the model's efficacy in predicting drug-induced cardiotoxicity compared to conventional assays.

Main Methods:

• Fabrication of cardiac tissues using cellular self-assembly of human induced pluripotent stem cells-derived cardiomyocytes in PDMS molds.
• Characterization of tissue constructs for protein expression, ECM production, sarcomeric organization, and contractile function.
• Functional assessment of drug response in 3D tissues versus 2D monolayers using contractility-based assays.

Main Results:

• The 3D cardiac tissue model demonstrated stable spontaneous contractions for up to 2 months.
• 3D cultured cells showed higher contraction speed and rate, with distinct drug responses compared to 2D cultures.
• Contractility-based assays were more sensitive in predicting cardiotoxicity, showing concordance with clinical data.

Conclusions:

• The developed 3D cardiac tissue model is effective for high-throughput drug toxicity screening.
• This model shows potential for early safety evaluation in drug development and personalized therapy.
• Functional contractility assays in 3D models offer improved prediction of drug-induced cardiotoxicity.